Actinogen Medical Exercises 340,002 ACWAO Options at $0.0375, Boosting Ordinary Shares on ASX

Details on Actinogen Medical’s Option Exercise and Share Capital Increase

Actinogen Medical Limited, trading on ASX under ticker ACW (ACN 086778476), completed a routine exercise of in-the-money options. The company confirmed that 340,002 ACWAO options were exercised on 28 July 2026, resulting in the issuance of an equal number of fully paid ordinary shares at AUD $0.0375 each. This reflects a standard capital management event where option holders converted their rights into underlying shares.

This option conversion expands ACW’s quoted equity base. Post-conversion, the company’s total issued ordinary share capital is 3,717,491,616 fully paid shares quoted on ASX. The newly issued shares rank equally with existing ordinary shares, ensuring no preferential treatment or subordination.

ACWAO Options: Exercise Price and Timing

The converted options, classified as ACWAO, expire on 11 September 2026 and have an exercise price of $0.0375 per share. These options became in-the-money when ACW’s share price exceeded the exercise price, prompting holders to exercise on 28 July 2026—well before the expiry date—indicating timely conversion under favourable market conditions.

The early exercise suggests confidence in the company’s share value. The $0.0375 strike price aligns with the option issuance terms, and exercising at this price implies the share price was at or above this level on the conversion date.

Capital Structure Post-Conversion and Quoted Securities Overview

After the quotation of the 340,002 new shares, Actinogen Medical’s quoted securities include 3,717,491,616 ordinary fully paid shares and two classes of quoted options: 277,249,773 ACWOC options expiring 30 September 2027 and 175,441,171 ACWOD options expiring 31 May 2027. These quoted options represent potential future dilution and are actively traded instruments for investors.

Additionally, ACW holds significant unquoted options: 71,873,727 ACWAP options expiring 15 September 2026 and 74,964,715 remaining ACWAO options expiring 11 September 2026, both with a $0.0375 exercise price. These unquoted options could lead to further equity dilution if exercised. The imminent September 2026 expiry dates warrant investor attention.

Impact of Option Exercise on Existing Shareholders

The conversion of 340,002 options results in incremental dilution for existing shareholders. Although the increase is modest relative to the total issued capital exceeding 3.7 billion shares, it slightly reduces non-participating shareholders’ ownership percentages.

More broadly, over 148 million unquoted options and 452 million quoted options remain outstanding, totaling approximately 600 million potential shares—equivalent to about 16% dilution if fully exercised. Shareholders should consider this overhang when evaluating future earnings per share and voting power.

Compliance with ASX Listing Rules and Quotation Application

Actinogen Medical’s application for quotation of the converted shares complies with ASX Listing Rules Appendix 2A. The company disclosed all relevant details including the number of securities, issue date, source (ACWAO options), exercise price, and currency (AUD), ensuring transparency for market participants.

The company confirmed that the new shares rank equally with existing ordinary shares and that the conversion was not part of an employee incentive scheme, indicating these options were likely issued to investors or for financing purposes rather than employee remuneration.

Upcoming Option Expiry Dates to Watch

Investors should closely monitor the expiry of ACWAP and ACWAO options scheduled for 11–15 September 2026. Remaining ACWAO options total 74,964,715, and ACWAP options total 71,873,727, both exercisable at $0.0375. The outcome of these expiries will significantly affect ACW’s share capital by mid-September 2026.

If exercised, these options could add approximately 146.8 million shares, substantially increasing the outstanding share count. Conversely, if they expire unexercised, dilution will be avoided. Investors should evaluate both scenarios and track company updates on option exercises.

Context of Actinogen Medical’s Capital Raising Strategy

The multiple option classes with varying expiry dates and exercise prices indicate Actinogen Medical’s strategic use of options for financing and capital raising. Options have been issued as part of capital raises, debt financing, or partnerships, allowing the company to defer cash inflows until exercise while providing investors defined return thresholds tied to share price performance.

This staggered capital structure offers flexibility but also implies potential dilution exceeding 600 million shares if all options convert, which shareholders should consider in their investment decisions.

ASX Listing Compliance and Disclosure

The company update serves as an Appendix 2A application under ASX Listing Rules, confirming all required disclosures including entity details, security type, number of securities, conversion source, and dates. The disclosure of unquoted securities ensures market transparency on ACW’s capital structure.

While the ASX system tracks total issued capital, figures may not reflect pending securities or concurrent capital management activities, so investors should remain vigilant.

Investor Notes on Share Ranking and Rights

The newly issued ordinary shares rank equally with all existing ordinary shares from their issue date, carrying identical voting, dividend, and asset rights. There are no special classes or preferential rights, maintaining a conventional and straightforward equity structure.

This equal ranking supports clear governance and shareholder communication, with one share equating to one vote and equal participation in dividends or capital returns. Investors should verify company documentation but can expect standard ordinary share rights.